Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children

Riyadh D. Muhammad, Reena Oza-Frank, Elizabeth Zell, Ruth Link-Gelles, K. M.Venkat Narayan, William Schaffner, Ann Thomas, Catherine Lexau, Nancy M. Bennett, Monica M. Farley, Lee H. Harrison, Arthur Reingold, James Hadler, Bernard Beall, Keith P. Klugman, Matthew R. Moore

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Background. Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23). Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has declined. The relative magnitude of these indirect effects among persons with and without PPV23 indications is unknown.Methods. We evaluated IPD incidence among adults with and without PPV23 indications using population- and laboratory-based data collected during 1998-2009 and estimates of the denominator populations with PPV23 indications from the National Health Interview Survey. We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.Results. The proportion of adult IPD cases with PPV23 indications increased from 51% before to 61% after PCV7 introduction (P <. 0001). PCV7-serotype IPD declined among all race, age, and PPV23 indication strata, ranging from 82% to 97%. Overall IPD rates declined in most strata, by up to 65%. However, incidence remained highest among adults with PPV23 indications compared with those without (34.9 vs 8.8 cases per 100 000 population, respectively). Apart from age ≥65 years, diabetes is now the most common indication for PPV23 (20% of all cases vs 10% of cases in 1998-1999).Conclusions. Although IPD rates have declined among adults, adults with underlying conditions remain at increased risk of IPD and comprise a larger proportion of adult IPD cases in 2009 compared with 2000. A continued increase in the prevalence of diabetes among US adults could lead to increased burden of pneumococcal disease.

Original languageEnglish (US)
Pages (from-to)e59-e67
JournalClinical Infectious Diseases
Volume56
Issue number5
DOIs
StatePublished - Feb 18 2013

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Epidemiology
Incidence
Population
Health Surveys
Chronic Disease
Interviews
Pediatrics

Keywords

  • chronic illnesses
  • herd effect
  • pneumococcal conjugate vaccine
  • pneumococcal disease
  • pneumococcal serotypes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Muhammad, R. D., Oza-Frank, R., Zell, E., Link-Gelles, R., Narayan, K. M. V., Schaffner, W., ... Moore, M. R. (2013). Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clinical Infectious Diseases, 56(5), e59-e67. https://doi.org/10.1093/cid/cis971

Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. / Muhammad, Riyadh D.; Oza-Frank, Reena; Zell, Elizabeth; Link-Gelles, Ruth; Narayan, K. M.Venkat; Schaffner, William; Thomas, Ann; Lexau, Catherine; Bennett, Nancy M.; Farley, Monica M.; Harrison, Lee H.; Reingold, Arthur; Hadler, James; Beall, Bernard; Klugman, Keith P.; Moore, Matthew R.

In: Clinical Infectious Diseases, Vol. 56, No. 5, 18.02.2013, p. e59-e67.

Research output: Contribution to journalReview article

Muhammad, RD, Oza-Frank, R, Zell, E, Link-Gelles, R, Narayan, KMV, Schaffner, W, Thomas, A, Lexau, C, Bennett, NM, Farley, MM, Harrison, LH, Reingold, A, Hadler, J, Beall, B, Klugman, KP & Moore, MR 2013, 'Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children', Clinical Infectious Diseases, vol. 56, no. 5, pp. e59-e67. https://doi.org/10.1093/cid/cis971
Muhammad, Riyadh D. ; Oza-Frank, Reena ; Zell, Elizabeth ; Link-Gelles, Ruth ; Narayan, K. M.Venkat ; Schaffner, William ; Thomas, Ann ; Lexau, Catherine ; Bennett, Nancy M. ; Farley, Monica M. ; Harrison, Lee H. ; Reingold, Arthur ; Hadler, James ; Beall, Bernard ; Klugman, Keith P. ; Moore, Matthew R. / Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. In: Clinical Infectious Diseases. 2013 ; Vol. 56, No. 5. pp. e59-e67.
@article{e4d78a0b10414562b6efd991e29d1c5d,
title = "Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children",
abstract = "Background. Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23). Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has declined. The relative magnitude of these indirect effects among persons with and without PPV23 indications is unknown.Methods. We evaluated IPD incidence among adults with and without PPV23 indications using population- and laboratory-based data collected during 1998-2009 and estimates of the denominator populations with PPV23 indications from the National Health Interview Survey. We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.Results. The proportion of adult IPD cases with PPV23 indications increased from 51{\%} before to 61{\%} after PCV7 introduction (P <. 0001). PCV7-serotype IPD declined among all race, age, and PPV23 indication strata, ranging from 82{\%} to 97{\%}. Overall IPD rates declined in most strata, by up to 65{\%}. However, incidence remained highest among adults with PPV23 indications compared with those without (34.9 vs 8.8 cases per 100 000 population, respectively). Apart from age ≥65 years, diabetes is now the most common indication for PPV23 (20{\%} of all cases vs 10{\%} of cases in 1998-1999).Conclusions. Although IPD rates have declined among adults, adults with underlying conditions remain at increased risk of IPD and comprise a larger proportion of adult IPD cases in 2009 compared with 2000. A continued increase in the prevalence of diabetes among US adults could lead to increased burden of pneumococcal disease.",
keywords = "chronic illnesses, herd effect, pneumococcal conjugate vaccine, pneumococcal disease, pneumococcal serotypes",
author = "Muhammad, {Riyadh D.} and Reena Oza-Frank and Elizabeth Zell and Ruth Link-Gelles and Narayan, {K. M.Venkat} and William Schaffner and Ann Thomas and Catherine Lexau and Bennett, {Nancy M.} and Farley, {Monica M.} and Harrison, {Lee H.} and Arthur Reingold and James Hadler and Bernard Beall and Klugman, {Keith P.} and Moore, {Matthew R.}",
year = "2013",
month = "2",
day = "18",
doi = "10.1093/cid/cis971",
language = "English (US)",
volume = "56",
pages = "e59--e67",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children

AU - Muhammad, Riyadh D.

AU - Oza-Frank, Reena

AU - Zell, Elizabeth

AU - Link-Gelles, Ruth

AU - Narayan, K. M.Venkat

AU - Schaffner, William

AU - Thomas, Ann

AU - Lexau, Catherine

AU - Bennett, Nancy M.

AU - Farley, Monica M.

AU - Harrison, Lee H.

AU - Reingold, Arthur

AU - Hadler, James

AU - Beall, Bernard

AU - Klugman, Keith P.

AU - Moore, Matthew R.

PY - 2013/2/18

Y1 - 2013/2/18

N2 - Background. Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23). Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has declined. The relative magnitude of these indirect effects among persons with and without PPV23 indications is unknown.Methods. We evaluated IPD incidence among adults with and without PPV23 indications using population- and laboratory-based data collected during 1998-2009 and estimates of the denominator populations with PPV23 indications from the National Health Interview Survey. We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.Results. The proportion of adult IPD cases with PPV23 indications increased from 51% before to 61% after PCV7 introduction (P <. 0001). PCV7-serotype IPD declined among all race, age, and PPV23 indication strata, ranging from 82% to 97%. Overall IPD rates declined in most strata, by up to 65%. However, incidence remained highest among adults with PPV23 indications compared with those without (34.9 vs 8.8 cases per 100 000 population, respectively). Apart from age ≥65 years, diabetes is now the most common indication for PPV23 (20% of all cases vs 10% of cases in 1998-1999).Conclusions. Although IPD rates have declined among adults, adults with underlying conditions remain at increased risk of IPD and comprise a larger proportion of adult IPD cases in 2009 compared with 2000. A continued increase in the prevalence of diabetes among US adults could lead to increased burden of pneumococcal disease.

AB - Background. Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23). Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has declined. The relative magnitude of these indirect effects among persons with and without PPV23 indications is unknown.Methods. We evaluated IPD incidence among adults with and without PPV23 indications using population- and laboratory-based data collected during 1998-2009 and estimates of the denominator populations with PPV23 indications from the National Health Interview Survey. We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.Results. The proportion of adult IPD cases with PPV23 indications increased from 51% before to 61% after PCV7 introduction (P <. 0001). PCV7-serotype IPD declined among all race, age, and PPV23 indication strata, ranging from 82% to 97%. Overall IPD rates declined in most strata, by up to 65%. However, incidence remained highest among adults with PPV23 indications compared with those without (34.9 vs 8.8 cases per 100 000 population, respectively). Apart from age ≥65 years, diabetes is now the most common indication for PPV23 (20% of all cases vs 10% of cases in 1998-1999).Conclusions. Although IPD rates have declined among adults, adults with underlying conditions remain at increased risk of IPD and comprise a larger proportion of adult IPD cases in 2009 compared with 2000. A continued increase in the prevalence of diabetes among US adults could lead to increased burden of pneumococcal disease.

KW - chronic illnesses

KW - herd effect

KW - pneumococcal conjugate vaccine

KW - pneumococcal disease

KW - pneumococcal serotypes

UR - http://www.scopus.com/inward/record.url?scp=84873644920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873644920&partnerID=8YFLogxK

U2 - 10.1093/cid/cis971

DO - 10.1093/cid/cis971

M3 - Review article

C2 - 23155149

AN - SCOPUS:84873644920

VL - 56

SP - e59-e67

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -